window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 24, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

European biotech

  • Biotech,Clinical Trials,European biotech,Events and Conferences,Gastroenterology

    Abivax to present nine obefazimod studies at DDW as Phase 3 ulcerative colitis data build

    Abivax will present nine scientific abstracts on obefazimod at Digestive [...]

    April 24, 2026
  • CDMOs & Manufacturing,Drug Development,European biotech,Logistics and distribution,Oncology,Partnerships & Funding,Supply Chain & Logistics

    Oncodesign expands ARRONAX deal to secure astatine-211 supply for radiotherapy research

    Oncodesign Services has expanded its collaboration with French research institute [...]

    April 18, 2026
  • Biologics & Biosimilars,Biotech,Drug discovery,European biotech,Healthcare leadership,Movers & Shakers,Opthalmology,Research & Development

    Link Biologics appoints Niall Martin to board as TSG-6 pipeline advances towards clinic

    Link Biologics has appointed Niall Martin to its board as [...]

    February 25, 2026
  • Biomanufacturing,CDMOs & Manufacturing,Drug Delivery & Formulation,European biotech,Facilities and infrastructure,Healthcare leadership,Manufacturing,Movers & Shakers,Pharmaceuticals and therapeutics

    Axplora expands lyophilisation capacity at Le Mans

    Axplora is investing several million euros to expand lyophilisation capacity [...]

    February 19, 2026
  • Clinical Development,Clinical Trials,European biotech,Mental health,Neurosciences,Research & Development

    FundaMental Pharma to present FMP374 preclinical data in treatment-resistant depression at Bio-Neuroscience Conference

    FundaMental Pharma GmbH will present new preclinical data on its [...]

    February 17, 2026
  • European biotech,Immunology,Movers & Shakers,Research & Development

    Nucleome Therapeutics appoints Michelle Morrow as chief scientific officer

    Nucleome Therapeutics has appointed Michelle Morrow as chief scientific officer, [...]

    February 16, 2026
  • Clinical Development,Drug Development,European biotech,Partnerships & Funding,Pharmaceuticals and therapeutics,Research & Development

    Syngene collaborates with Johns Hopkins University to advance early-stage drug discovery

    Syngene International has entered a collaboration with Johns Hopkins University [...]

    February 12, 2026
  • Biotech,Clinical Development,European biotech,Immunology,Oncology,Partnerships & Funding,Research & Development

    Kahimmune Therapeutics signs exclusive licensing agreement with Gustave Roussy and SATT Paris-Saclay

    Kahimmune Therapeutics has signed an exclusive licensing agreement with Gustave [...]

    February 2, 2026
  • Clinical Development,Clinical studies,Drug Delivery & Formulation,European biotech,Obesity,Research & Development

    Nanexa targets next-generation ‘fat jab’ with monthly semaglutide delivery platform

    Sweden-based Nanexa has reported preclinical data for a long-acting semaglutide [...]

    January 29, 2026
  • Biotech,Cell & Gene Therapy,Clinical Development,Clinical Trials,European biotech,Opthalmology

    PulseSight completes Phase 1 dosing of gene therapy candidate PST-611 in dry AMD and geographic atrophy

    PulseSight Therapeutics has completed dosing in its Phase 1 clinical [...]

    January 26, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Neomorph raises $100 million to advance NEO-811 Phase 1/2 cancer trial and molecular glue degrader pipeline
    Categories: Biotech, Clinical Trials, Drug discovery, Funding, Oncology, Partnerships & Funding, Pharmaceuticals and therapeutics, Research & Development, Technology and platforms
  • NICE expands Lokelma access for hyperkalaemia after draft recommendation
    Categories: Cardiovascular diseases, Chronic diseases, Market Access & Commercialization, Pharmaceuticals and therapeutics, Regulatory Affairs
  • Oncodesign expands ARRONAX deal to secure astatine-211 supply for radiotherapy research
    Categories: CDMOs & Manufacturing, Drug Development, European biotech, Logistics and distribution, Oncology, Partnerships & Funding, Supply Chain & Logistics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top